Principal Financial Group Inc. Reduces Holdings in Collegium Pharmaceutical, Inc. $COLL

Principal Financial Group Inc. decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,295,028 shares of the specialty pharmaceutical company’s stock after selling 18,634 shares during the period. Principal Financial Group Inc. owned about 4.00% of Collegium Pharmaceutical worth $42,827,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wedge Capital Management L L P NC bought a new position in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $2,697,000. Vanguard Group Inc. raised its position in shares of Collegium Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Collegium Pharmaceutical by 193.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 211,757 shares of the specialty pharmaceutical company’s stock valued at $7,409,000 after buying an additional 139,689 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after buying an additional 518,721 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Collegium Pharmaceutical by 161.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock worth $23,692,000 after buying an additional 316,109 shares in the last quarter.

Collegium Pharmaceutical Price Performance

NASDAQ:COLL opened at $36.08 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The company has a market capitalization of $1.17 billion, a P/E ratio of 17.69 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 12 month low of $29.19 and a 12 month high of $50.79. The business’s 50-day moving average is $34.62 and its 200 day moving average is $38.34.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. During the same quarter last year, the business posted $1.49 EPS. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. On average, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of recent analyst reports. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Finally, Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Collegium Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.